Protective Effects of Oroxylin A against Doxorubicin-Induced Cardiotoxicity via the Activation of Sirt1 in Mice

Figure 1

OA treatment attenuated cardiac dysfunction in DOX-treated mice. (a) Bodyweight in the indicated group (). (b) The ratio of heart weight to tibial length (). (c, d) Serum and cardiac CK-MB (). (e, f) Serum and cardiac LDH (). (g) Heart rate in the indicated groups (). (h) EF in the indicated groups (). (i, j) ±dP/dt in DOX-treated mice (). (k, l) LVSP and LVEDP in DOX-treated mice (). Differences between multiple groups were determined by one-way ANOVA followed by Tukey’s test. vs. control group, ^# vs. DOX group.

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)